URGN UroGen Pharma Ltd. Stock Quote

URGN [NASD]

Index	-	P/E	-	EPS (ttm)	-5.91	Insider Own	2.20%	Shs Outstand	22.15M	Perf Week	-14.75%
Market Cap	339.59M	Forward P/E	-	EPS next Y	-2.94	Insider Trans	1.64%	Shs Float	19.36M	Perf Month	-12.76%
Income	-128.50M	PEG	-	EPS next Q	-1.29	Inst Own	75.50%	Short Float	12.09%	Perf Quarter	-41.03%
Sales	11.80M	P/S	28.78	EPS this Y	-15.20%	Inst Trans	2.61%	Short Ratio	13.27	Perf Half Y	-35.30%
Book/sh	4.35	P/B	3.54	EPS next Y	39.50%	ROA	-87.10%	Target Price	-	Perf Year	-37.58%
Cash/sh	4.62	P/C	3.33	EPS next 5Y	-	ROE	-100.80%	52W Range	17.00 - 30.89	Perf YTD	-14.65%
Dividend	-	P/FCF	-	EPS past 5Y	-36.70%	ROI	-135.00%	52W High	-50.21%	Beta	1.20
Dividend %	-	Quick Ratio	5.30	Sales past 5Y	-	Gross Margin	91.40%	52W Low	-9.53%	ATR	1.28
Employees	187	Current Ratio	5.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	29.16	Volatility	10.22% 6.86%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	25.80%	Profit Margin	-	Rel Volume	2.81	Prev Close	18.16
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 13 BMO	Payout	-	Avg Volume	176.29K	Price	15.38
Recom	1.70	SMA20	-19.46%	SMA50	-19.75%	SMA200	-26.73%	Volume	495,522	Change	-15.31%

Apr-16-20

Reiterated

H.C. Wainwright

Buy

$53 → $57

Apr-13-20

Reiterated

H.C. Wainwright

Buy

$75 → $53

Jan-09-20

Initiated

National Securities

Neutral

$37

May-30-19

Initiated

JP Morgan

Neutral

May-29-19

Initiated

Goldman

Neutral

Jan-29-19

Initiated

H.C. Wainwright

Buy

$82

Nov-08-18

Resumed

Jefferies

Buy

Apr-04-18

Upgrade

Raymond James

Mkt Perform → Outperform

Jan-02-18

Initiated

Ladenburg Thalmann

Buy

$50

Nov-15-17

Reiterated

Oppenheimer

Outperform

$32 → $51

Nov-15-17

Downgrade

Raymond James

Outperform → Mkt Perform

May-13-21 12:11PM	UROGEN PHARMA (URGN) Reports Q1 Loss, Misses Revenue Estimates Zacks -15.31%
07:30AM	UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments Business Wire
06:30AM	UroGen Pharma Ltd. to Host Earnings Call ACCESSWIRE
May-12-21 08:11AM	How Much Are UroGen Pharma Ltd. (NASDAQ:URGN) Insiders Spending On Buying Shares? Simply Wall St.
May-06-21 08:00AM	UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021 Business Wire
Mar-18-21 09:15AM	UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates Zacks -7.44%
08:17AM	UroGen Pharma: Q4 Earnings Insights Benzinga
08:00AM	UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments Business Wire
07:30AM	UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments Business Wire
06:30AM	UroGen Pharma Ltd. to Host Earnings Call ACCESSWIRE
Mar-15-21 08:00AM	UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline Business Wire
Mar-12-21 04:44AM	Is UroGen Pharma Ltd.'s (NASDAQ:URGN) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Mar-11-21 08:00AM	UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021 Business Wire
Mar-05-21 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-23-21 08:00AM	UroGen Pharma Announces March 2021 Conference Schedule Business Wire -8.01%
Jan-26-21 07:01AM	UroGen Pharma Ltd. (NASDAQ:URGN): Are Analysts Optimistic? Simply Wall St.
Jan-19-21 07:00AM	Idaho Champion Drills Oxide Gold and Silver Near Historic Pits at Champagne Gold Project ACCESSWIRE
Jan-13-21 08:00AM	UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer Business Wire
Jan-06-21 08:00AM	UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference Business Wire +5.61%
Dec-18-20 04:36AM	UroGen Pharma's(NASDAQ:URGN) Share Price Is Down 50% Over The Past Three Years. Simply Wall St.
Dec-16-20 07:20AM	Idaho Champion Gold Completes 2020 Exploration Program at Champagne Gold Project ACCESSWIRE
Dec-11-20 08:35AM	Metals & Mining Investor Conference Presentations Now Available for On-Demand Viewing PR Newswire
Dec-07-20 07:00AM	Idaho Champion Extends Target at the Baner Gold Project with High Gold in Rock Chips ACCESSWIRE
Dec-04-20 08:42AM	Metals & Mining Live Virtual Investor Conference December 8th and 9th PR Newswire
08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-03-20 08:00AM	UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology Business Wire
Nov-29-20 07:57PM	Hedge Funds Arent Crazy About UroGen Pharma Ltd. (URGN) Anymore Insider Monkey
Nov-17-20 08:00AM	Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Business Wire
Nov-12-20 08:00AM	UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think Simply Wall St.
Nov-11-20 08:00AM	Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGens Jelmyto® Effective January 1, 2021 Business Wire
Nov-10-20 08:00AM	UroGen Pharma Announces November 2020 Conference Schedule Business Wire
Nov-09-20 07:00PM	UroGen Pharma Ltd. (URGN) Q3 2020 Earnings Call Transcript Motley Fool
08:33AM	Recap: UroGen Pharma Q3 Earnings Benzinga
08:00AM	UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments Business Wire
06:30AM	UroGen Pharma Ltd. to Host Earnings Call ACCESSWIRE
Nov-02-20 08:00AM	UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 Business Wire
Oct-27-20 06:50AM	Idaho Champion Gold Mobilizes Second Core Rig to Champagne Project ACCESSWIRE +7.27%
Oct-07-20 12:58PM	We Think UroGen Pharma (NASDAQ:URGN) Needs To Drive Business Growth Carefully Simply Wall St. +6.44%
Oct-05-20 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-15-20 12:14PM	Oppenheimer: 3 Stocks That Could Surge Over 100% From Current Levels TipRanks
Sep-10-20 08:00AM	UroGen Pharma Announces September 2020 Conference Schedule Business Wire
Sep-09-20 08:00AM	UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth Business Wire
Sep-04-20 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-27-20 08:00AM	UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence Business Wire -10.74%
Aug-10-20 05:00PM	UroGen Pharma Ltd. (URGN) Q2 2020 Earnings Call Transcript Motley Fool +14.08%
08:33AM	What You Need To Know About UroGen Pharma Ltd.'s (NASDAQ:URGN) Investor Composition Simply Wall St.
08:00AM	UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments Business Wire
Aug-03-20 08:00AM	UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 Business Wire
Jun-15-20 08:43PM	Hedge Funds Are Selling UroGen Pharma Ltd. (URGN) Insider Monkey
Jun-05-20 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-01-20 08:00AM	UroGen Pharma to Present at Jefferies Virtual Healthcare Conference Business Wire
May-15-20 09:01AM	UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer Business Wire
09:00AM	UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto in Patients with Low-Grade Upper Tract Urothelial Cancer Business Wire
May-09-20 02:31PM	UroGen Pharma Ltd. (URGN) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 08:00AM	UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments Business Wire
May-01-20 08:00AM	UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020 Business Wire
Apr-30-20 09:05AM	UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans Simply Wall St. -8.86%
08:00AM	The Lancet Oncology Publishes Details of UroGen Pharmas Pivotal OLYMPUS Trial Business Wire
Apr-21-20 12:34PM	With FDA Approvals in Hand, These 2 Biotech Stocks Are on Wall Streets Radar TipRanks
Apr-16-20 10:37AM	UroGen shares jump 10% on FDA approval of rare cancer treatment MarketWatch +5.23%
08:09AM	The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant Benzinga
Apr-15-20 06:22PM	UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer Business Wire -14.71%
Apr-06-20 08:53AM	UroGen (URGN) Looks Good: Stock Adds 8.1% in Session Zacks +9.09%
Apr-03-20 08:00AM	UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Business Wire +8.06%
Mar-23-20 08:00AM	UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development Business Wire +18.57%
Mar-16-20 11:45AM	Is UroGen Pharma Ltd. (NASDAQ:URGN) A Volatile Stock? Simply Wall St. -22.19%
Mar-06-20 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-02-20 08:00AM	UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments Business Wire
Feb-25-20 08:00AM	UroGen Pharma Announces March 2020 Investor Conference Schedule Business Wire
Feb-24-20 08:00AM	UroGen Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 2, 2020 Business Wire
Jan-30-20 08:59AM	Are Insiders Buying UroGen Pharma Ltd. (NASDAQ:URGN) Stock? Simply Wall St.
Jan-08-20 08:00AM	UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-19-19 08:00AM	UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101 Business Wire
Dec-17-19 07:36PM	Is UroGen Pharma Ltd. (URGN) A Good Stock To Buy? Insider Monkey
Dec-16-19 12:00PM	Volatility 101: Should UroGen Pharma (NASDAQ:URGN) Shares Have Dropped 29%? Simply Wall St. +5.07%
Dec-06-19 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.67%
Dec-01-19 03:06PM	Weekly CEO Buys Highlight GuruFocus.com
Nov-18-19 08:00AM	UroGen to Present at November 2019 Investor Conferences Business Wire
Nov-12-19 08:00AM	UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments Business Wire +13.58%
07:20AM	The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga
Nov-11-19 08:00AM	UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers Business Wire
Nov-06-19 10:16AM	We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate Simply Wall St.
08:00AM	UroGen Pharma to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 Business Wire
Sep-30-19 08:00AM	UroGen To Present at October 2019 Investor Conference Business Wire
Sep-24-19 04:01PM	UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances Business Wire
10:25AM	UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer Business Wire
Sep-18-19 12:15PM	Does UroGen Pharma Ltd. (NASDAQ:URGN) Have A High Beta? Simply Wall St.
Sep-10-19 08:00AM	UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness Business Wire
Sep-06-19 04:05PM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-13-19 03:05PM	Estimating The Intrinsic Value Of UroGen Pharma Ltd. (NASDAQ:URGN) Simply Wall St. +5.58%
Aug-12-19 04:23PM	UroGen Pharma Ltd. (URGN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-10-19 07:11AM	3 Stocks the World's Best Investors Are Buying Right Now Motley Fool
Aug-09-19 08:00AM	UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments Business Wire
Aug-05-19 08:00AM	UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 Business Wire
Jul-23-19 10:43AM	Here's Why the Best Is Yet to Come for UroGen Pharma Motley Fool
Jul-16-19 09:48AM	UroGen Pharma Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-05-19 05:14PM	Hedge Funds Have Never Been This Bullish On UroGen Pharma Ltd. (URGN) Insider Monkey
Jul-01-19 08:00AM	UroGen Pharma Joins Russell 3000® Index Business Wire
May-30-19 08:00AM	UroGen Pharma to Present at June 2019 Investor Conferences Business Wire
May-26-19 08:18AM	3 Top Stocks That Aren't on Wall Street's Radar Motley Fool

UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-302 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. It also has a strategic research agreement with the Johns Hopkins University to explore the potential of checkpoint inhibitors combined with RTGel in glioblastoma multiform. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schoenberg Mark	Chief Medical Officer	Apr 30	Sale	20.00	243	4,860	21,132	May 04 01:58 PM
Schoenberg Mark	Chief Medical Officer	Apr 26	Sale	19.63	89	1,747	20,875	Apr 27 01:44 PM
Belldegrun Arie	Director	Mar 24	Option Exercise	5.00	3,241	16,205	245,452	Apr 22 05:19 PM
Nussbaum Ran	Director	Mar 24	Option Exercise	5.00	1,030	5,150	1,465,199	Apr 22 05:18 PM
Schoenberg Mark	Chief Medical Officer	Jan 31	Sale	22.07	1,076	23,747	20,755	Feb 02 02:53 PM
Schoenberg Mark	Chief Medical Officer	Jan 26	Sale	22.12	100	2,212	19,831	Jan 26 05:20 PM
Barrett Elizabeth A.	Chief Executive Officer	Dec 14	Buy	18.50	10,000	185,000	229,117	Dec 15 05:27 PM
Barrett Elizabeth A.	Chief Executive Officer	Dec 04	Option Exercise	0.00	61,652	0	219,117	Dec 04 04:35 PM
Schoenberg Mark	Chief Medical Officer	Dec 04	Sale	19.85	662	13,141	19,723	Dec 07 03:59 PM
Schoenberg Mark	Chief Medical Officer	Oct 26	Sale	20.95	101	2,116	19,343	Oct 28 02:12 PM
PFREUNDSCHUH PETER P.	Chief Financial Officer	Oct 15	Sale	21.77	2,400	52,248	10,405	Oct 16 03:41 PM
Schoenberg Mark	Chief Medical Officer	Sep 04	Sale	20.20	348	7,030	19,236	Sep 08 04:48 PM
PFREUNDSCHUH PETER P.	Chief Financial Officer	Sep 01	Sale	22.82	509	11,615	7,888	Sep 01 02:37 PM
PFREUNDSCHUH PETER P.	Chief Financial Officer	Jul 27	Sale	23.51	141	3,315	7,355	Jul 28 05:34 PM
Schoenberg Mark	Chief Medical Officer	Jul 27	Sale	23.51	70	1,646	18,543	Jul 28 05:32 PM
Schoenberg Mark	Chief Medical Officer	Jun 04	Sale	27.51	349	9,602	18,404	Jun 05 02:31 PM
PFREUNDSCHUH PETER P.	Chief Financial Officer	May 20	Sale	25.07	358	8,975	7,079	May 20 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience